Cargando…
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
BACKGROUND: No pharmacological treatment has been demonstrated to provide a functional benefit for persons with Huntington’s disease (HD). Pridopidine is a sigma-1-receptor agonist shown to have beneficial effects in preclinical models of HD. OBJECTIVE: To further explore the effect of pridopidine o...
Autores principales: | McGarry, Andrew, Leinonen, Mika, Kieburtz, Karl, Geva, Michal, Olanow, C. Warren, Hayden, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836066/ https://www.ncbi.nlm.nih.gov/pubmed/33164941 http://dx.doi.org/10.3233/JHD-200440 |
Ejemplares similares
-
A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic
por: Kieburtz, Karl, et al.
Publicado: (2020) -
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018) -
Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023) -
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016) -
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
por: Francardo, Veronica, et al.
Publicado: (2019)